Purple Biotech (PPBT) Competitors $0.60 +0.04 (+6.60%) Closing price 04:00 PM EasternExtended Trading$0.60 -0.01 (-0.95%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. NKGN, ALZN, CAPS, CDIO, VIVS, ACXP, PMCB, ENSC, SBFM, and PLRZShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include NKGen Biotech (NKGN), Alzamend Neuro (ALZN), Capstone Therapeutics (CAPS), Cardio Diagnostics (CDIO), VivoSim Labs (VIVS), Acurx Pharmaceuticals (ACXP), Nuvilex (PMCB), Ensysce Biosciences (ENSC), Sunshine Biopharma (SBFM), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors NKGen Biotech Alzamend Neuro Capstone Therapeutics Cardio Diagnostics VivoSim Labs Acurx Pharmaceuticals Nuvilex Ensysce Biosciences Sunshine Biopharma Polyrizon Purple Biotech (NASDAQ:PPBT) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Which has more risk & volatility, PPBT or NKGN? Purple Biotech has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Is PPBT or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Purple BiotechN/A -14.00% -12.52% NKGen Biotech N/A N/A -479.36% Does the media prefer PPBT or NKGN? In the previous week, Purple Biotech had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for Purple Biotech and 1 mentions for NKGen Biotech. Purple Biotech's average media sentiment score of 0.69 beat NKGen Biotech's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Purple Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in PPBT or NKGN? 9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, PPBT or NKGN? Purple Biotech is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPurple BiotechN/AN/A-$7.24M-$0.42-1.44NKGen BiotechN/AN/A-$82.94M-$2.45-0.05 Do analysts rate PPBT or NKGN? Purple Biotech presently has a consensus price target of $33.00, indicating a potential upside of 5,375.36%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Purple Biotech is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPurple Biotech beats NKGen Biotech on 8 of the 13 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56M$3.09B$5.70B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.4421.3075.8626.51Price / SalesN/A380.87491.12165.50Price / CashN/A44.4425.8129.89Price / Book0.059.6112.846.32Net Income-$7.24M-$53.28M$3.28B$270.51M7 Day Performance1.72%0.32%0.22%2.15%1 Month Performance-74.61%4.59%4.61%6.35%1 Year PerformanceN/A9.24%68.33%25.49% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.7714 of 5 stars$0.60+6.6%$33.00+5,375.4%N/A$1.56MN/A-1.4420NKGNNKGen Biotech0.134 of 5 stars$0.15+5.3%N/A-82.9%$6.74MN/A-0.03N/AGap DownALZNAlzamend Neuro3.7826 of 5 stars$2.36+1.7%$45.00+1,806.8%-86.5%$6.72MN/A0.004Positive NewsCAPSCapstone TherapeuticsN/A$1.16-1.7%N/AN/A$6.59M$44.88M0.0038CDIOCardio Diagnostics1.4651 of 5 stars$3.63-2.2%N/A-58.1%$6.54M$40K0.001VIVSVivoSim Labs0.5431 of 5 stars$2.49-0.8%N/AN/A$6.53M$140K-0.2420Gap UpACXPAcurx Pharmaceuticals2.2253 of 5 stars$4.13+1.2%$31.00+650.6%-89.8%$6.47MN/A-0.393Analyst DowngradePMCBNuvilex1.5415 of 5 stars$1.13+20.1%N/A-45.8%$6.40MN/A0.444Earnings ReportGap DownHigh Trading VolumeENSCEnsysce Biosciences0.8924 of 5 stars$2.10-1.4%N/A-57.7%$6.34M$5.21M-0.5210SBFMSunshine Biopharma2.908 of 5 stars$1.41+4.1%$15.00+963.8%-47.1%$6.17M$34.87M-0.013PLRZPolyrizonN/A$1.00-2.0%N/AN/A$6.11MN/A0.00N/A Related Companies and Tools Related Companies NKGen Biotech Competitors Alzamend Neuro Competitors Capstone Therapeutics Competitors Cardio Diagnostics Competitors VivoSim Labs Competitors Acurx Pharmaceuticals Competitors Nuvilex Competitors Ensysce Biosciences Competitors Sunshine Biopharma Competitors Polyrizon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
